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ABSTRACT: A series of tri[(p-carboranylmethylthio)tetraﬂuorophenyl]porphyrin conjugates of linear and branched polyamines, glucose, arginine, tri(ethylene glycol), and Tyr-D-Arg-Phe-βAla (YRFA) peptide were synthesized. These conjugates were
investigated for their BBB permeability in human hCMEC/D3 brain
endothelial cells, and their cytotoxicity and uptake were assessed using
human glioma T98G cells. For comparison purposes, a symmetric
tetra[(p-carboranylmethylthio)tetraﬂuorophenyl]porphyrin was also
synthesized, and its crystal structure was obtained. All porphyrin
conjugates show low dark cytotoxicity (IC50 > 400 μM) and low
phototoxicity (IC50 > 100 μM at 1.5 J/cm2) toward T98G cells. All
conjugates were eﬃciently taken up by T98G cells, particularly the
cationic polyamine and arginine conjugates, and were localized in
multiple cellular organelles, including mitochondria and lysosomes. All compounds showed relatively low in vitro BBB
permeability compared with that of lucifer yellow because of their higher molecular weight, hydrophobicity, and tendency for
aggregation in solution. Within this series, the branched polyamine and YRFA conjugates showed the highest permeability
coeﬃcient, whereas the glucose conjugate showed the lowest permeability coeﬃcient.

■

INTRODUCTION
Boron neutron capture therapy (BNCT) is a binary treatment
methodology for brain tumors and other cancers that involves
the irradiation of 10B-containing tumors with low-energy
thermal or epithermal neutrons.1−3 The nuclear reaction
produces excited 11B nuclei, which spontaneously ﬁssion to
give cytotoxic high linear energy transfer (high-LET) alpha and
lithium-7 particles, γ radiation, and about 2.4 MeV of kinetic
energy, as shown by the following equation:
10

during BNCT. Two BNCT drugs have been used clinically, the
sodium salt of the sulfhydryl boron hydride Na2B12H11SH,
known as BSH, and L-4-dihydroxy-borylphenylalanine known
as BPA, either alone or in combination for the treatment of
high-grade gliomas and recurrent head and neck cancers.4−6
Although BSH and BPA have shown to be safe and eﬃcacious
in BNCT clinical trials, improved boron-delivery agents of low
toxicity and with the ability to deliver high amounts of boron
into tumor cells have been the focus of research in recent
decades.7,8 Among these, boron-containing porphyrins are
particularly promising because of their demonstrated high
tumor cell uptake and retention, ability to deliver therapeutic
amounts of boron intracellularly, and ﬂuorescence and
photosensitizing properties, which facilitate the quantiﬁcation
of tissue-localized boron and the possibility of using photodynamic therapy (PDT) as an adjuvant treatment for
BNCT.9,10 PDT combines a photosensitizer, light, and oxygen
to generate reactive oxygen species, including singlet oxygen,
that are highly cytotoxic to tissues.11,12 Two porphyrin-based
macrocycles are FDA-approved as PDT photosensitizers, and
several others are under investigation for the PDT treatment of

B + 1n → 7Li 3 + + 4 He 2 + + γ + 2.4 MeV

The high-LET particles have relatively short path lengths in
tissues of about one cell diameter, limiting the destructive eﬀect
to 10B-containing malignant cells. Therefore, BNCT can
potentially destroy tumor cells dispersed in normal brain tissue
if suﬃcient amounts of 10B (∼20 μg/g weight or ∼109 atoms/
cell) and low-energy neutrons are selectively delivered. Boron10 is a nonradioactive isotope with 20% natural abundance that
can be incorporated into BNCT agents at the 95−96% level
from 10B-enriched starting materials. Eﬀective boron-delivery
agents must show low systemic toxicity, deliver therapeutic
amounts of boron to target tumors with high (>5) tumor-tobrain and tumor-to-blood concentration ratios, and clear
rapidly from normal tissues while persisting in the tumor
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Scheme 1a

a
Conditions: (a) mercaptomethyl-p-carborane, K2CO3, DMF, rt, 48 h (89% for 1); (b) Zn(OAc)2, methanol/CH2Cl2,rt; (c) TFA/chloroform 1:1,
rt, 4 h (combined 3 steps, 30% for 2); (d) H2N-(Boc)-polyamine or H2N-(CH2CH2O)3CH2CH2CO2tBu, NMP, 100 °C, 4 h, (95−96%); (e) 1-thiolβ-D-glucose tetraacetate, K2CO3, DMF, rt, 48 h (95%); (f) NaOMe, methanol/chloroform, rt, 2 h (93%); (g) L-arginine or YRFA on solid support,
HATU, DIEA, DMF, rt. (65−89%).

Figure 1. Porphyrin-polyamine conjugates17 evaluated in the in vitro BBB model permeability studies.

12-fold. Herein, we report the synthesis and conjugation of a
ﬂuorinated p-carbonylmethylthioporphyrin to linear and
branched polyamines, glucose, arginine, and Tyr-D-Arg-Phe-βAla (YRFA) peptide. Fluorinated porphyrins have been shown
to have increased biological eﬃcacy compared with that of their
nonﬂuorinated analogues,19−21 and they also allow visualization
and quantiﬁcation of tissue-localized drug via 18F-PET
imaging.22 The conjugation of polyamines to porphyrins has
been shown to lead to increased tumor cell uptake as a result of
an upregulated polyamine transport system and/or the
interaction of the cationic ammonium groups with plasma
membrane phosphates.17,23−25 Similarly, porphyrins containing
one or more arginine groups have demonstrated enhanced

various malignant and nonmalignant conditions in dermatology, cardiology, and ophthalmology.13 The combination of
BNCT and PDT is particularly attractive for the treatment of
high-grade gliomas and melanomas because it targets diﬀerent
mechanisms of tumor cell destruction and increases the overall
therapeutic eﬀect. We have reported the synthesis and
investigation of promising dual sensitizers for application in
combined PDT and BNCT treatment, H2TCP14,15 and
TPFC,16 that show eﬃcient photosensitizing activity against
melanotic melanomas. We have also demonstrated that
conjugation of a boron-containing porphyrin to polyamines
(Figure 1)17 or to a cell-penetrating peptide sequence18
signiﬁcantly increases their cellular uptake by approximately
6719
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phyrin (2) was prepared from TPPF in 30% yield, and conjugate 6 was
prepared from porphyrin 2 in 95% yield, as we have recently
described.17 All compounds were obtained in ≥95% purity, as
determined by HPLC (see Supporting Information).
YRFA Synthesis. An Applied Biosystems Pioneer peptide synthesis
system was used to synthesize the YRFA peptide using Fmoc-PALPEG-PS on a 0.2 mmol scale using the Fmoc strategy of solid-phase
peptide synthesis. The ﬁrst Fmoc-protected amino acid was
conjugated to the resin twice in 4-fold excess before loading of the
next amino acid in the sequence so as to have 100% loading of the ﬁrst
amino acid and optimize the reaction yield. Coupling reagents HOBt/
TBTU were used, and the peptide sequence was monitored using
MALDI after cleaving from the resin using a cleavage cocktail TFA/
phenol/TIS/H2O (88:5:2:5).
5,10,15,20-Tetra(p-carboranylmethylthiotetraﬂuorophenyl)porphyrin (1). To a solution of TPPF (19.5 mg, 0.0200 mmol) in 2
mL of anhydrous DMF were added anhydrous K2CO3 (31.5 mg, 0.120
mmol) and mercaptomethyl-p-carborane37 (22.8 mg, 0.0800 mmol).
The reaction mixture was stirred at room temperature for 48 h. The
resulting solution was diluted with ethyl acetate (50 mL) and washed
with brine (2 × 50 mL). The organic layer was dried over anhydrous
sodium sulfate, and the solvents were evaporated under reduced
pressure. The resulting residue was puriﬁed by column chromatography using 3:7 petroleum ether/chloroform for elution, giving 30.0
mg (89%) of the title porphyrin, mp >300 °C. UV−vis (DMSO) λmax
(ε/M−1 cm−1) 416 (467 600), 511 (46 800), 555 (19 500), 585 (12
100), 650 (9 200). 1H NMR (CDCl3, 400 MHz): δ 8.93 (s, 8H, β-H),
3.47 (s, 8H, SCH2), 2.16−3.02 (m, 44H, carborane-BH and CH),
−2.87 (s, 2H, NH). 13C NMR (CDCl3, 100 MHz): δ 147.78, 147.63,
147.48, 145.30, 145.15, 144.99, 131.93, 131.28, 120.99, 120.80, 120.61,
115.69, 115.50, 115.31, 104.33, 81.87, 59.22, 53.57, 51.82, 40.60,
31.64, 30.93, 29.72, 29.04, 19.15, 14.13. 19F NMR (acetone-d6, 233.33
MHz): δ −136.3 to −135.7 (m, 8F), −140.6 to −139.8 (m, 8F). MS
(MALDI-TOF) m/z calcd for C56H64F16N4B40S4 [M + H], 1656.773;
found, 1656.791.
X-ray Crystallographic Data for Porphyrin 1. Data was
collected at 90 K with Cu Kα radiation (λ = 1.54178 Å) on a Bruker
Kappa Apex-II diﬀractometer. C56H62B40F16N4S4·2.28CHCl3, triclinic
space group P−1, a = 12.1535(15), b = 14.690(2), c = 15.015(2) Å, α
= 71.943(6), β = 76.081(9), γ = 68.140(8)°, V = 2341.5(5) Å3, Z = 1.
One of the two independent carborane cages was disordered into two
orientations, with reﬁned occupancies 0.748(5)/0.252(5). The
partially occupied carboranes were treated as rigid bodies in the
reﬁnement using the geometry of the ordered carborane. The
chloroform solvent was disordered, and its contribution to the
structure factors was removed using the SQUEEZE procedure. Final R
= 0.077, Rw = 0.229 for 517 reﬁned parameters and 8266 independent
reﬂections having θmax = 69.6°. The CIF has been deposited at the
Cambridge Crystallographic Data Centre (CCDC 927692).
Porphyrin Conjugate 3. To a solution of porphyrin 217 (14.9 mg,
0.0100 mmol) in 2 mL of NMP was added 4-(2-aminoethyl)-1,7bis(tert-butoxycarbonyl)-1,4,7-triazaheptane (4.50 mg, 0.015 mmol),
and the mixture was heated for 4 h at 100 °C. After cooling to room
temperature, the solution was diluted with ethyl acetate (50 mL) and
washed with brine (5 × 50 mL). The organic layer was dried over
anhydrous sodium sulfate, and the solvents were evaporated under
reduced pressure to give a reddish brown residue. This residue was
puriﬁed by silica gel column chromatography using 9:1 dichloromethane/ethyl acetate for elution to yield pure product (17.0 mg, 96%
yield), mp >300 °C. UV−vis (DMSO) λmax (ε/M−1 cm−1) 416 (469
200), 511 (45 200), 555 (18 400), 585 (11 400), 650 (8 100). 1H
NMR (CDCl3, 400 MHz): δ 9.04 (s, 2H, β-H), 8.92 (s, 6H, β-H), 3.74
(s, 2H, NCH2), 3.47 (s, 6H, SCH2), 3.32 (br s, 6H, NCH2), 2.90 (s,
2H, NCH2), 2.79 (s, 2H, NCH2), 1.62−2.68 (m, 33H, carborane-BH
and CH), 1.49 (s, 18H, OtBu), −2.85 (s, 2H, NH). 13C NMR (CDCl3,
100 MHz): δ 156.72, 147.86, 145.16, 138.51, 135.81, 121.04, 115.14,
106.28, 104.07, 81.92, 79.71, 60.77, 59.29, 54.37, 43.05, 40.59, 38.62,
28.78, 21.15, 14.13. 19F-NMR (acetone-d6, 233.33 MHz): δ −136.3 to
.6 (m, 6F), −139.9 to −s139.1 (m, 6F), −141.4 (d, J = 15.9 Hz, 2F),
−164.9 (d, J = 16.3 Hz, 2F). MS (MALDI-TOF) m/z calcd for

cellular uptake due, in part, to the planar geometry and charge
delocalization of the guanidinium group which is uniquely
suited for interaction with plasma membrane phosphates.26,27
The conjugation of carbohydrates to porphyrin derivatives is
another attractive strategy for increasing the solubility and
cellular uptake of photosensitizers due to the targeting of
carbohydrate-binding lectins highly expressed in tumor
cells.28−30 Among these, glucose derivatives are particularly
promising due to the overexpression of glucose transporters
(GLUT)31 in tumor cells and in the brain capillary endothelial
cells that form the blood−brain barrier (BBB).32 The BBB
largely restricts the movement of hydrophilic, high molecular
weight molecules between the blood and the brain interstitial
ﬂuid, and this constitutes a major challenge for boron delivery
in BNCT of brain tumors.7−10,32,33 A variety of transporters
and receptors are expressed at the BBB for the transport of
nutrients and metabolites into the brain, including GLUT1,
GLUT3, and μ-opioid receptors. Opioid peptides, including
dermorphin and its derivatives such as Tyr-D-Arg-Phe-β-Ala
(YRFA), have high aﬃnity for μ-opioid receptors and can cross
the BBB via adsorptive-mediated endocytosis.34−36 Therefore,
the conjugation of a boron-containing porphyrin to polyamines,
glucose, arginine and the opioid peptide YRFA could lead to
increased BBB permeability and tumor cell uptake for eﬃcient
intracellular boron delivery. In this article, we report the
synthesis and investigation of a series of conjugates to a
ﬂuorinated carboranylporphyrin in human glioma T98G and
hCMEC/D3 cells, and we compare their cytotoxicity and ability
to cross the BBB and to localize within tumor cells.

■

EXPERIMENTAL SECTION

Chemistry. Commercially available reagents and solvents (HPLC
grade) were purchased from Sigma-Aldrich or Acros Organics and
used without further puriﬁcation. para-Carborane was purchased from
Katchem, Inc. Anhydrous methanol was prepared by distillation from
magnesium and stored under nitrogen over 3 Å molecular sieves.
Anhydrous THF was prepared by distillation from sodium and
benzophenone. Analytical thin-layer chromatography (TLC) was
performed on polyester-backed TLC plates 254 (precoated, 200 μm,
Sorbent Technologies), and silica gel 60 (70−230 mesh, Merk) was
used for column chromatography. 1H and 13C NMR spectra were
obtained using a Bruker AV-4 400 MHz spectrometer, and 19F NMR,
on a Bruker DPX-250 250 MHz spectrometer; chemical shifts are
expressed in ppm relative to CDCl3 (7.26 ppm, 1H; 77.0 ppm,13C),
(CD3)2CO (2.05 ppm, 1H; 29.84 and 206.26 ppm, 13C). Electronic
absorption spectra were measured on a PerkinElmer Lambda 35 UV−
vis spectrophotometer. Mass analyses were conducted at the LSU
Mass Spectrometry Facility on a Bruker Omniﬂex MALDI-TOF mass
spectrometer or on an Applied Biosystems QSTAR XL (for HRMSESI). Melting points were measured on a Thomas Hoover melting
point apparatus. Reversed-phase HPLC was performed on a Waters
system including a 2545 quaternary gradient module pump with a
2489 UV−vis detector and a fraction collector III. An analytical
column (4.6 × 250 mm XBridgeTM BED300 C18, 5 μm) was used for
the puriﬁcation of all conjugates. For conjugates 3, 4, and 7, a stepwise
gradient from 0 to 100% buﬀer B (0.1% TFA, acetonitrile) in the ﬁrst
10 min to 50% B and 50% C during the next 10 min to 100% B for the
next 10 min was used. Conjugate 5 was puriﬁed using a stepwise
gradient 0−100% buﬀer C (0.1% TFA, acetone) with buﬀer A (0.1%
TFA, H2O) over 45 min. Conjugate 6 was puriﬁed using a stepwise
gradient 10−90% buﬀer B with buﬀer A. Conjugate 8 was puriﬁed
using a stepwise gradient 70% buﬀer A and 30% buﬀer B for 1 min,
20% buﬀer A and 80% buﬀer B for 10 min, 10% buﬀer A and 80%
buﬀer B, 10% buﬀer C for 12 min, 65% buﬀer B and 35% buﬀer C for
25 min, and 70% buﬀer A and 30% buﬀer B for 61 min. 5,10,15-Tri(pcarboranylmethylthiotetraﬂuorophenyl)-20-pentaﬂuorophenylpor6720
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C69H82F16N8B30O4S3 [M], 1811.839; found, 1811.878. This Bocprotected conjugate was dissolved in 1:1 TFA/dichloromethane (2
mL) in a 10 mL round-bottomed ﬂask and stirred at room
temperature for 6 h. The solvent was evaporated under reduced
pressure to give a residue, which was puriﬁed by HPLC to give 15 mg
(95%) of conjugate 3, mp >300 °C. HPLC tR = 26.332. UV−vis
(DMSO) λmax (ε/M−1 cm−1) 416 (467 900), 511 (45 300), 555 (18
900), 585 (11 500), 650 (8 100). 1H NMR (acetone-d6, 400 MHz): δ
9.26 (s, 8H, β-H), 3.58 (s, 6H, SCH2), 2.23−3.53 (m, 45H, NCH2,
carborane-BH and CH). 13C NMR (acetone-d6, 100 MHz): δ 147.76,
145.86, 139.01, 136.11, 122.34, 114.18, 107.18, 102.07, 82.82, 79.91,
61.07, 58.89, 55.07, 43.45, 40.39, 39.12, 29.98, 14.13.19F NMR
(acetone-d6, 233.33 MHz): δ −136.4 to −135.6 (m, 6F), −139.7 to
−138.7 (m, 6F), −140.5 (d, J = 14.7 Hz, 2F), −164.5 (d, J = 13.4 Hz,
2F).
Porphyrin Conjugate 4. To porphyrin 2 (14.9 mg, 0.0100 mmol)
in a 10 mL round-bottomed ﬂask were added N-(2-aminoethyl)-N-[2[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-,1,1-dimethylethyl ester
(5.2 mg, 0.015 mmol) and 2 mL of NMP, and the ﬁnal mixture was
heated for 4 h at 100 °C. After cooling to room temperature, ethyl
acetate (25 mL) was added to the reaction mixture, and the organic
layer was washed ﬁve times with brine solution (5 × 25 mL). The
resulting mixture was dried over sodium sulfate, and the solvent was
evaporated under reduced pressure to give a reddish brown residue.
This residue was ﬁrst passed through silica gel using dichloromethane
for elution followed by column chromatography using dichloromethane/ethyl acetate (9:1) to yield pure product (17.5 mg) in 96%
yield, mp >300 °C. UV−vis (DMSO) λmax (ε/M−1 cm−1) 416 (465
800), 511 (44 800), 555 (19 600), 585 (12 900), 650 (8 200). 1H
NMR (CDCl3, 400 MHz): δ 9.09 (s, 2H, β-H), 8.95 (s, 6H, β-H), 3.90
(s, 2H, NCH2), 3.85 (s, 2H, NCH2), 3.42−3.53 (m, 10H, SCH2,
NCH2), 1.81−2.96 (m, 33H, carborane-BH and CH), −2.83 (s, 2H,
NH). 13C NMR (CDCl3, 100 MHz): δ 157.0, 156.28, 147.81, 147.68,
145.33, 145.19, 145.05, 121.69, 121.28, 121.09, 120.90, 120.51, 115.53,
115.34, 115.15, 106.41, 103.99, 103.80, 84.46, 81.91, 81.04, 79.67,
60.42, 59.23, 40.63, 28.43. 19F NMR (acetone-d6, 233.33 MHz): δ
−136.3 to −135.4 (m, 6F), −140.2 to −139.3 (m, 6F), −140.9 (d, J =
16.0 Hz, 2F), −164.8 (d, J = 14.8 Hz, 2F). MS (MALDI-TOF) m/z
calcd for C67H77F16N7B30S3O4 [M]+, 1768.796; found, 1768.783. This
Boc-protected conjugate was dissolved in 1:1 TFA/dichloromethane
(2 mL) in a 10 mL round-bottomed ﬂask and stirred at room
temperature for 6 h. The solvent was evaporated under reduced
pressure to give a residue, which was puriﬁed by HPLC to give 95.6%
(15.5 mg) of conjugate 4, mp >300 °C. HPLC tR = 23.866. UV−vis
(DMSO) λmax (ε/M−1 cm−1) 415 (468 000), 511 (45 300), 555 (18
200), 585 (11 800), 650 (8 100). 1H NMR (acetone-d6, 400 MHz): δ
9.14−9.25 (br s, 8H, β-H), 3.59 (s, 6H, SCH2), 2.27−3.34 (m, 41H,
carborane-BH and CH, NCH2). 13C NMR (acetone-d6, 100 MHz): δ
147.51, 145.23, 145.15, 121.48, 121.29, 120.60, 120.01, 115.14, 115.05,
104.21, 103.90, 84.26, 81.41, 81.02, 79.81, 59.13, 40.63, 14.43. 19F
NMR (acetone-d6, 233.33 MHz): δ −136.6 to −134.8 (m, 6F), −140.2
to −139.4 (m, 6F), −140.1 (d, J = 16.0 Hz, 2F), −164.7 (d, J = 14.1
Hz, 2F).
Porphyrin Conjugate 5. To a solution of porphyrin 2 (14.9 mg,
0.0100 mmol) in 2 mL DMF were added K2CO3 (1.1 mg, 0.020
mmol) and 1-thiol-β-D-glucose tetraacetate (5.5 mg, 0.015 mmol). The
mixture was stirred for 48 h at room temperature, washed with water
(10 mL), and extracted with ethyl acetate (3 × 25 mL). The organic
layer was dried over anhydrous sodium sulfate, and the solvent was
evaporated under reduced pressure. The product was puriﬁed by silica
gel column chromatography ﬁrst using dichloromethane for elution
followed by 7:3 dichloromethane/ethyl acetate to give the protected
conjugate (17.4 mg) in 95% yield, mp 289−292 °C. UV−vis (DMSO)
λmax (ε/M−1 cm−1) 417 (420 100), 510 (35 700), 555 (17 500), 585
(11 100), 650 (6 800). 1H NMR (CDCl3, 250 MHz): δ 9.09 (s, 2H, βH), 9.01 (s, 6H, β-H), 5.25−5.44 (m, 4H, CH), 4.39 (s, 2H, CH), 3.98
(s, 1H, CH), 3.49 (s, 6H, SCH2), 1.24−3.26 (m, 45H, carborane-BH
and CH, OAc), −2.79 (s, 2H, NH). 13C NMR (CDCl3, 62.5 MHz): δ
170.58, 170.12, 169.41, 169.33, 148.33, 144.36, 131.31, 128.75, 122.03,
121.02, 120.71, 120.41, 115.74, 115.44, 115.13, 112.11, 111.78, 104.29,

103.52, 84.43, 81.77, 73.87, 70.53, 68.01, 61.75, 59.13, 40.47, 20.56.
19
F NMR (CDCl3, 233.33 MHz): δ −136.2 to −135.4 (m, 6F),
−139.8 to −138.0 (m, 6F), −144.2 (d, J = 18.6 Hz, 2F), −162.8 (d, J =
17.2 Hz, 2F). To a solution of the above compound (17.4 mg, 0.0095
mmol) in 10 mL of 1:1 chloroform/methanol was added 50 μL of 0.5
M NaOMe in methanol, and the ﬁnal solution was stirred at room
temperature for 2 h. The solvents were evaporated under reduced
pressure to give a red color residue, which was puriﬁed by silica gel
chromatography ﬁrst using dichloromethane for elution followed by
3:7 dichloromethane/ethyl acetate. The pure conjugate was obtained
(14.68 mg) in 93% yield, mp 289−292 °C. HPLC tR = 19.433. UV−vis
(DMSO) λmax (ε/M−1 cm−1) 417 (440 010), 510 (37 600), 555 (17
500), 585 (11 100), 650 (9 100). 1H NMR (CDCl3, 250 MHz): δ 8.94
(s, 2H, β-H), 8.86 (s, 6H, β-H), 5.32 (br s, 4H, OH), 4.81 (br s, 1H),
4.07−4.21 (m, 4H, CH), 3.81 (s, 1H, CH), 1.43−3.60 (m, 39H,
carborane-BH and CH, SCH2). 13C NMR (CDCl3, 62.5 MHz): δ
148.26, 144.26, 130.84, 120.50, 120.41, 115.25, 112.29, 104.19, 86.83,
81.58, 79.97, 73.74, 69.43, 61.91, 58.90, 40.46, 40.14, 29.58. 19F NMR
(acetone-d6, 233.33 MHz): δ −135.7 to −134.9 (m, 6F), −140.0 to
−139.3 (m, 6F), −144.9 (d, J = 19.6 Hz, 2F), −162.4 (d, J = 14.2 Hz,
2F).
Porphyrin Conjugate 7. To a solution of conjugate 617 (16.9 mg,
0.0100 mmol) in 0.5 mL DMF was added DIEA (7.8 mg, 0.060
mmol), and the mixture was stirred for 10 min at room temperature.
HATU (3.82 mg, 0.0100 mmol) was added, and stirring was continued
for 15 min. L-Arginine amide dihydrochloride (2.4 mg, 0.010 mmol)
was added, and the ﬁnal reaction mixture was stirred for 48 h at 37 °C.
The solvent was removed under reduced pressure, and the resulting
residue was puriﬁed by HPLC to give 15.6 mg (85% yield) of
conjugate 7, mp >300 °C. HPLC tR = 25.856. UV−vis (DMSO) λmax
(ε/M−1 cm−1) 416 (458 100), 511 (44 100), 555 (17 100), 585 (11
100), 650 (7 500). 1H NMR (acetone-d6, 400 MHz): δ 8.9−9.5 (br s,
8H, β-H), 3.29−3.91 (m, 25H, SCH2, NCH2, arginine-CH2 and CH,
OCH2), 1.78−3.07 (m, 45H, arginine-CH2, carborane-BH and CH).
13
C NMR (acetone-d6, 100 MHz): δ 173.20, 171.48, 157.95, 148.60,
145.65, 121.04, 115.14, 106.53, 104.31, 70.32, 70.24, 70.15, 70.06,
67.0, 59.89, 51.31, 40.47, 36.23, 24.80, 22.42, 13.46. 19F NMR
(acetone-d6, 233.33 MHz): δ −135.2 to −134.6 (m, 6F), −139.6 to
−138.9 (m, 6F), −140.8 (d, J = 15.4 Hz, 2F), −164.1 (d, J = 12.1 Hz,
2F).
Porphyrin Conjugate 8. A solution of conjugate 617 (16.91 mg,
0.01 mmol) in DMF (0.5 mL) and DIEA (7.8 mg, 0.06 mmol) was
stirred for 10 min at room temperature. HOBT (1.5 mg, 0.01 mmol)
and DEPBT (3.0 mg, 0.01 mmol) were added, and the mixture was
stirred at room temperature for another 15 min. The activated
porphyrin was added to the peptide on PAL-PEG-PS resin (5.6 mg,
0.01 mmol), and the ﬁnal mixture was stirred for 96 h. Then, the resin
was washed under vacuum several times with DMF followed by
methanol and DCM. A cleavage cocktail, TFA/phenol/TIS/H2O
(88:5:2:5), was added with constant shaking for 4 h. Then, the mixture
was washed with TFA into a ﬂask and concentrated under vacuum.
Cold diethyl ether was added to the residue, and the mixture was
centrifuged. The obtained red colored solid was puriﬁed by HPLC to
yield 7 mg (65%) of conjugate 8, mp > 300 °C. HPLC tR = 25.698.
UV−vis (DMSO) λmax (ε/M−1 cm−1) 416 (462 100), 511 (44 300),
555 (17 900), 585 (12 100), 650 (8 100). 1H NMR (acetone-d6, 400
MHz): δ 9.4 (s, 2H, β-H), 9.32 (s, 6H, β-H), 7.16−7.28 (m, 4H, o-PhH), 7.13 (s, 1H, p-Ph-H), 7.03−7.10 (d, J = 3.44 Hz, 2H, m-Ph-H),
6.72−6.79 (d, J = 4.56 Hz, 2H, m-Ph-H), 3.85−4.01 (m, 4H, OCH2),
3.63−3.78 (m, 12H, OCH2), 3.6 (s, 6H, SCH2), 3.4−3.51 (m, 6H,
NCH2), 1.3−3.21 (m, 56H, carborane-BH and CH, peptide-CH),
−2.89 (s, 2H, NH). 13C NMR (acetone-d6, 100 MHz): δ 172.47,
162.62, 159.01, 158.62, 156.72, 148.11, 145.65, 138.27, 130.33, 129.25,
128.19, 126.32, 123.95, 117.22, 115.24, 114.36, 81.68, 70.12, 66.92,
60.03, 56.58, 55.60, 52.65, 45.27, 40.34, 36.65, 35.67, 26.57, 24.60,
19.43. 19F NMR (acetone-d6, 233.33 MHz): δ −135.6 to −134.8 (m,
6F), −140.1 to −139.0 (m, 6F), −140.9 (d, J = 15.9 Hz, 2F), −164.7
(d, J = 16.5 Hz, 2F). MS (MALDI-TOF) m/z calcd for
C89H103F16N13B30S3O9 [M + H], 2224.990; found, 2224.998. MSMS (MALDI- TOF-TOF) m/z calcd for C89H98F16N12B30S3O9,
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Information, Figure S10. The cells were incubated (37 °C, 95%
humidity, 5% CO2) for 0, 30, and 60 min, and at the end of each
incubation time, 5 × 100 μL of solution from the lower chamber was
pipetted out, and 500 μL of fresh HBSS buﬀer was added back to the
lower chamber. The ﬁve 100 μL (ﬁve replicates) solutions that were
collected from the lower chamber were added to a 96-well plate. The
porphyrin and LY concentrations were determined by ﬂuorescence
emission, read at 415/650 nm and 420/540 nm (excitation/emission),
respectively, using a BMG FLUOstar plate reader. The permeability
coeﬃcients (P) were determined following the clearance principle,
according to the equation below,38 where Cf is the ﬁnal concentration
of the compound (ng/mL), C0 is the initial concentration of
compound (ng/mL), tf is the ﬁnal time (min), t0 is the initial time
(min), and A is the surface area of the ﬁlter (cm2).

2205.807; C85H96F16N11B30S3O7, 2108.591; C71H77F16N7B30S3O6,
1888.408; C70H76F16N6B30S3O5, 1805.461; found, 2224.998 [PorPEG-YRFA-CONH2 + H]+, 2205.800 [(PorPEG-YRFA-CO) −
2H]+, 2108.591 [PorPEG-YRF], 1888.405 [(PorPEG-Y-CONH2 +
K +H]+, 1805.420 [PorpPEG-Y].
Cell Studies. All tissue culture medium and reagents were
purchased from Invitrogen (Carlsbad, CA). Human glioma T98G
cells were purchased from ATCC and cultured in ATCC-formulated
Eagle’s minimum essential medium containing 10% FBS and 1%
antibiotic (penicillin/streptomycin). The hCMEC/D3 cells were
obtained from coauthors from the Institut COCHIN (Paris, France).
All compound solutions were ﬁlter-sterilized using a 0.22 μm syringe
ﬁlter.
Dark Cytotoxicity. Human T98G cells (10 000 per well) were
plated in a Costar 96-well plate and allowed to grow for 36 h.
Conjugate stock solutions (32 mM) were prepared in DMSO and then
diluted into ﬁnal working concentrations (25, 50, 100, 200, 400 μM).
The cells were exposed to increasing concentrations of porphyrin
conjugate up to 400 μM and incubated overnight. The loading
medium was removed, and the cells were washed with 100 μL of PBS.
Medium containing CellTiter Blue (Promega) (120 μL) was added as
per the manufacturer’s instructions. After a 4 h incubation, the
cytotoxicity was measured by reading the ﬂuorescence at 520/584 nm
using a BMG FLUOstar plate reader. The signal was normalized to
100% viable (untreated) cells and 0% viable (treated with 0.2%
saponin from Sigma) cells.
Phototoxicity. Human T98G cells were prepared as described
above and treated with conjugate concentrations of 0, 6.25, 12.5, 25,
50, and 100 μM. After compound loading, the medium was removed
and replaced with medium containing 50 mM HEPES, pH 7.4. The
cells were exposed to a NewPort light system containing a 175 W
halogen lamp for 20 min, ﬁltered through a water ﬁlter to provide an
approximately 1.5 J/cm2 light dose. The cells were kept cool by placing
the culture on a 50C Echotherm chilling/heating plate (Torrey Pines
Sci. Inc.). The cells were returned to the incubator overnight and
assayed for cytotoxicity as described above.
Time-Dependent Uptake. Human T98G cells were prepared as
described above and exposed to 10 μM of each conjugate for 0, 1, 2, 4,
8, and 24 h. At the end of the incubation period, the loading medium
was removed, and the cells were washed with 200 μL of PBS. The cells
were solubilized upon addition of 100 μL of 0.25% Triton X-100
(Calbiochem) in PBS. To determine the porphyrin concentration,
ﬂuorescence emission was read at 415/650 nm (excitation/emission)
using a BMG FLUOstar plate reader. The cell number was quantiﬁed
using the CyQuant cell proliferation assay (Invitrogen) as per the
manufacturer’s instructions, and the uptake was expressed in terms of
compound concentration (nanomolar) per cell.
Microscopy. Human HEp2 cells were incubated in a glass bottom
6-well plate (MatTek) and allowed to grow for 48 h. The cells were
exposed to 10 μM of each porphyrin conjugate for 6 h. Organelle
tracers were obtained from Invitrogen and used at the following
concentrations: LysoSensor Green, 50 nM; MitoTracker Green, 250
nM; ER Tracker Blue/White, 100 nM; and BODIPY FL C5 Ceramide,
1 mM. The organelle tracers were diluted in medium, and the cells
were incubated concurrently with conjugate and tracers for 30 min
before washing three times with PBS and imaging by microscopy.
Images were acquired using a Leica DM RXA2 upright microscope
with 40× NA 0.8 dip objective lens and DAPI, GFP, and Texas Red
ﬁlter cubes (Chroma Technologies).
hCMEC/D3 Cell Line (In Vitro BBB Model). The human brain
capillary endothelial hCMEC/D3 cells were incubated in a 6-well, 0.4
μm porosity PET transwell plate (Corning) and allowed to grow for
48 h to form a model BBB monolayer. EBM-2 medium containing 5%
FBS, 1% penicillin/streptomycin, hydrocortisone, ascorbic acid,
chemically deﬁned lipid concentrate (1/100), HEPES, and bFGF
was used as growth medium. A 0.5 mL sample of each porphyrin
conjugate or standard lucifer yellow (LY) at 1 mg/mL concentration
in HBSS (pH 6.7−7.8) was added to the upper chamber (mimicking
the blood compartment), and 1.5 mL of HBSS buﬀer was added to the
lower chamber (mimicking the cerebral compartment), see Supporting

P=

■

(Cf − C0)
1
×
(tf − t0)
A ·C0·60

RESULTS AND DISCUSSION
Synthesis and Characterization. Commercially available
TPPF was the starting material used for the preparation of the
p-carborane-containing porphrins 1−8, as shown in Scheme 1.
The nucleophilic substitution of the p-ﬂuorine groups of TPPF
is a convenient strategy for the synthesis of functionalized
porphyrins for therapeutic and other applications.21 Reaction of
TPPF with 6 equiv of 1-mercaptomethyl-p-carborane37 in DMF
and in the presence of K2CO3 produced the symmetric
tetra(carboranyl)porphyrin 1 in 89% yield. The tri(carboranyl)porphyrin 2 was obtained using 4 equiv of 1-mercaptomethyl-pcarborane, as we recently reported,17 and was used for the
preparation of conjugates 3−8. The p-carborane clusters were
chosen as the source of boron in these porphyrins due to their
higher stability toward deboronation in the presence of bases
and nucleophiles compared to that of the most commonly used
o-carboranes.16,39 Slow recrystallization of porphyrin 1 by slow
diﬀusion of hexane into chloroform gave crystals suitable for Xray analysis. As shown in Figure 2, the molecule lies on an
inversion center in the crystal, and the porphyrin core is nearly
planar, with the best plane of its 24 atoms having a mean

Figure 2. X-ray crystal structure of porphyrin 1.
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Table 1. Cytotoxicitya for Porphyrin Conjugates Using
Human Glioma T98G Cells and Major Localization Sites in
Human HEp2 Cells

deviation of 0.022 Å and a maximum of 0.048(4) Å. The phenyl
planes are nearly orthogonal to the porphyrin plane, forming
dihedral angles of 89.1(1) and 83.8(1)° with it. The four sulfur
atoms are coplanar and approximate a square (13.46 Å per
side). The centroids of the p-carborane cages are nearly in the
porphyrin plane, lying alternately 0.60 Å above and 0.90 Å
below it. One of the two independent p-carborane cages is
disordered into two orientations in approximately 3:1 ratio (not
shown in Figure 1). This is the ﬁrst and only structure of a
porphyrin-bearing p-carborane in the Cambridge Structural
Database (CSD),40 although 16 structures have appeared of
porphyrins with o-carborane. These tend to have structures
similar to that of 1, with near-planar porphyrin cores, frequently
lying on inversion centers. However, in a few of these ocarboranylporphyrins, steric eﬀects41 or substitution patterns of
lower symmetry42 lead to nonplanar porphyrin cores.
Substitution of the p-ﬂuorophenyl group of porphyrin 2 with
the primary amine group of commercially available Bocprotected polyamines (linear and branched polyamines), 1thiol-β-D-glucose tetraacetate, and tert-butyl-12-amino-4,7,10trioxadodecanoate, followed by deprotection, gave the corresponding conjugates 3−6 in nearly quantitative yields (>95%)
after reverse-phase HPLC puriﬁcation. The carboxyl-terminated
tri(ethylene glycol)porphyrin 617 was conjugated in solution
phase to L-arginine, using HATU and DIEA, to produce
conjugate 7 in 89% yield and in solid phase to YRFA, using
DEPBT, HOBt, and DIEA, to produce 8 in 65% yield after
HPLC puriﬁcations.
One linear and one branched (containing an additional
aminoethyl moiety) polyamine was conjugated to porphyrin 2
to evaluate the eﬀect of their chemical structure and overall
cationic charge on cytotoxicity, cellular uptake, and BBB
permeability. The arginine conjugate 7 was prepared for
comparison purposes because the guanidinium group has been
previously observed to enhance binding to phosphatecontaining plasma membranes and to increase cellular
uptake.26,27 The tri(ethylene glycol) group in conjugates 7
and 8 increases the solubility of porphyrin macrocycles and has
been shown to further enhance their cellular uptake.27,43 The
glucose conjugate 5 was prepared to investigate the potential
targeting of lectins and of glucose transporters (GLUT)
overexpressed on tumor cells and the BBB.30−32 YRFA is a
tetrapeptide with the sequence Tyr-D-Arg-Phe-β-Ala with
demonstrated high aﬃnity and selectivity for μ-opioid receptors
as well as good enzymatic stability.34−36
Studies in T98G cells. Cytotoxicity. The concentrationdependent dark and phototoxicity of all porphyrin conjugates
were investigated in T98G cells, and the results are summarized
in Table 1 (see also Figures S8 and S9 of the Supporting
Information). None of the conjugates were toxic to cells, with
determined IC50 > 400 μM in the dark and IC50 > 100 μM
upon irradiation with a low light dose (1.5 J/cm2). These
results are in agreement with our previous studies on a series of
spermine derivatives 9−15 17 (see Figure 1) and of
cobaltabisdicarbollide-containing porphyrins conjugated to a
PEG43 or arginine-rich peptide18 that showed low toxicities,
probably as a result of the attachment of the carborane clusters
to the macrocycle rather than to the biomolecule. The observed
low cytotoxicity of this series of compounds is important for
their use as boron-delivery agents because of the high boron
concentration requirement in BNCT (>20 μg/g weight), and
their low phototoxicity makes them unsuitable for application
as PDT photosensitizers.

compd

dark toxicity IC50
(μM)

phototoxicity IC50
(μM)

major sites of
localization

1
3
4
5
617
7
8

>400
>400
>400
>400
296
>400
>400

>100
>100
>100
>100
>100
>100
>100

Lyso, Mito, Golgi
Mito, Golgi, ER
Lyso, Mito, Golgi
Lyso, Mito, Golgi
Lyso, Mito, ER
Lyso, Mito, Golgi
Lyso, Mito, Golgi

a

CellTiter Blue assay; light dose ∼ 1.5 J/cm2.

Cellular Uptake. The time-dependent uptake of conjugates
1, 3, 4, 5, 7, and 8 into glioma T98G cells was evaluated at a
concentration of 10 μM over 24 h, and the results are shown in
Figure 3. All conjugates accumulated rapidly within cells in the

Figure 3. Time-dependent uptake of porphyrin 1 (red) and conjugates
3 (green), 4 (orange), 5 (black), 7 (blue), and 8 (purple) at 10 μM by
human glioma T98G cells.

ﬁrst 2 h, after which a plateau was reached except for the
glucose conjugate 5, which showed continuous uptake over the
24 h period investigated, suggesting GLUT-mediated transport.
At 4, 8, and 24 h, the L-arginine conjugate 7 showed the highest
uptake followed by the tetracarboranylporphyrin 1. We have
previously observed that the cellular uptake depends on the
number of carborane clusters at the periphery of the porphyrin
macrocycle44,45 and that tetracarboranylporphyrins tend to
accumulate to a higher extent than their tricarboranylporphyrin
analogues18,44 as a result of their increased hydrophobicity. We
have also reported that the extent of cellular uptake of
polyamine conjugates 9−1517 (Figure 1) generally increases
with the hydrophilicity of the conjugates and that compared
with that of 9, conjugates 10 and 11, bearing additional
aminoethyl moieties, are taken up more eﬃciently by T98G
cells. In agreement with these observations, the branched
polyamine conjugate 3 showed higher uptake at all time points
investigated compared with that of conjugate 4, probably as a
result of its greater positive charge and hydrophilicity. On the
other hand, the most eﬃciently internalized at times >4 h was
the L-arginine conjugate 7, probably due to the unique ability of
the guanidinium group to form bidentate hydrogen bonds with
membrane-containing phosphates, as we and many others have
previously observed.26,27,46
Intracellular Localization. To investigate the main sites of
intracellular localization of the conjugates, ﬂuorescence
microscopy was conducted using HEp2 rather than T98G
cells because the former spread nicely on glass coverslips,
facilitating imaging. The organelle-speciﬁc ﬂuorescent probes
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ERTracker Blue/White (ER), MitoTracker Green (mitochondria), BODIPY-FL Ceramide (Golgi), and LysoSensor Green
(lysosomes) were used in the overlay experiments, as shown in
Figures 4 and 5 (for conjugates 3 and 8, respectively) and in the
Supporting Information, Figures S12−S15 (for porphyrins 1, 4,
5, and 7, respectively); the data are also summarized in Table 1.
The polyamine conjugates localized preferentially in mitochondria, Golgi, and ER, the glucose conjugate 5 was mainly found
in the lysosomes and mitochondria, and the arginine and YRFA
conjugates were mainly found in the lysosomes, Golgi, and
mitochondria. These results are in agreement with our previous
observations on the intracellular distribution of porphyrin
conjugates.17,18,26,27 The multiple sites of intracellular localization observed for these porphyrins could lead to damage to
multiple intracellular sites, resulting in more eﬀective tumor cell
destruction.
BBB Permeability Studies in hCMEC/D3 cells. The
hCMEC/D3 cell line retains most of the morphological and
functional characteristics of human brain endothelial cells,
including many of the drug transporters found in human BBB,
and it is believed to be an excellent model for studies of BBB
function and drug transport processes.47−51 The transport of
boron-containing molecules across the BBB is largely hindered,
which poses a major challenge in BNCT upon systemic drug
delivery, and the observed selective uptake of certain boronated
porphyrins into brain tumor is believed to be due to the
breakdown of the BBB within the tumor region, whereas an
intact BBB prevents the uptake in normal brain.52 Because free
diﬀusion across the BBB is limited to a small number of
compounds of low molecular weight (<400 Da), we
hypothesized that conjugation of a carboranylporphyrin to
molecules that target BBB receptors (GLUT and μ-opioid) or
macrocycles containing cationic groups for enhanced interactions with membrane phosphates could increase their
transport across brain endothelial cells. The transport of several
molecules across hCMEC/D3 cell monolayers, including
sugars, ﬂavonoids, liposomes, and oligopeptides, have been
previously reported, and several receptors and transporters have
been identiﬁed,53−58 including P-glycoprotein (P-gp), breast
cancer resistance protein (BCRP), multidrug resistanceassociated proteins (MRP), solute carriers (SLC), and
proton-coupled oligopeptide transporters (POT). However,
this BBB model has not previously been used for the
investigation of boron-delivery agents for BNCT or of
porphyrin derivatives.
To investigate the BBB permeability of our carboranylporphyrin 1 and conjugates 3−15, we used the hCMEC/D3 cell
line as an in vitro model for the human BBB, comparing their
permeability to that of standard lucifer yellow (LY), a small
ﬂuorescent molecule with a 429 Da molecular weight and 536
nm emission that contains two sulfonates and one cabohydrazine group. The BBB model (see Supporting Information,
Figure S10) consists of a basolateral chamber (mimicking the
cerebral compartment) and an apical chamber (mimicking the
blood compartment) containing a monolayered cell membrane
to which the porphyrins were added. The permeability studies
were completed within 1 h to ensure that the cell monolayer
retained its function and integrity in the absence of cell
medium. The permeabilities of the porphyrin conjugates are
given as permeability coeﬃcients (P), determined as previously
described.38 Table 2 summarizes the P values obtained for LY
and the porphyrin conjugates 1 and 3−15. The P value
obtained for LY is in agreement with that reported in the

Figure 4. Subcellular ﬂuorescence of conjugate 3 in HEp2 cells at 10
μM for 6 h: (a) phase contrast, (b) overlay of the ﬂuorescence of 3
and phase contrast, (c) ER Tracker Blue/White ﬂuorescence, (e)
MitoTracker Green ﬂuorescence, (g) BODIPY Ceramide, (i)
LysoSensor Green ﬂuorescence, and (d, f, h, j) overlays of organelle
tracers with the ﬂuorescence of 3. Scale bar, 10 μm.
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Table 2. Permeabilty Coeﬃcients (P) for Porphyrin
Conjugates and Lucifer Yellow (LY) Using Human
Endothelial hCMEC/D3 Cells
compd
1
3
4
5
6
7
8
9
10
11
12
13
14
15
LY

P × 10−6 (cm/s)
1.36
2.32
0.82
0.62
1.18
1.44
1.71
1.31
0.82
1.21
3.29
1.10
0.87
1.47
21.7

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.04
0.02
0.02
0.05
0.03
0.03
0.06
0.08
0.06
0.04
0.03
0.06
0.08
0.05
0.30

literature,48,49 and the lower P values measured for all
porphyrin conjugates reﬂect the integrity of the brain
endothelial monolayer. The permeability of molecules across
hCMEC/D3 cell monolayers depends on molecular weight,
hydrophobic character, and the targeting of speciﬁc receptors
on the cell surface. The higher molecular weight for all
porphyrin conjugates in comparison with that of LY along with
their higher hydrophobic character and tendency for
aggregation in aqueous conditions45 account for their lower
permeability coeﬃcients in comparison with that of LY. Within
the series of porphyrins investigated, the polyamine conjugates
3 and 12 showed higher P values, followed by the YRFA
conjugate 8, whereas conjugate 5 had the lowest P value. It is
interesting that porphyrins 1 and 3 with the highest uptake into
T98G cells after 1 h (see Figure 2) also showed high
permeability, whereas conjugate 5, the least taken up by T98G
cells after 1 h, showed the lowest permeability. In addition, the
observed permeability is enhanced for the branched polyamine
conjugate 3 in comparison with that of the linear polyamine
conjugate 4 containing one less ethylamine arm, as was also
observed in the uptake into T98G cells (Figure 2). These
results suggest that the glucose conjugate 5 is not targeting the
GLUT receptors expressed at the surface of hCMEC/D3 cells,
which might be due to its tendency for aggregation in aqueous
solutions. On the other hand, it has been previously observed
that the hCMEC/D3 cells express amino acid and oligopeptide
transporters, such as hPHT1 and hPHT2, whereas they express
little or no hPepT1 and hPepT2,59 and no studies were
conducted on the expression of μ-opioid receptors. The higher
P value found for the opioid-targeted YRFA conjugate 8
compared with those of untargeted porphyrins 1 and 6 as well
as the P values found for most polyamine conjugates, with the
exception of 3 and 12, suggests that conjugate 8 might be
targeting receptors on the cell surface. It is possible that
positively charged conjugates have enhanced interactions with
negatively charged cell membranes, favoring their transport
across the cell monolayer. Indeed, the arginine conjugate 7
showed increased permeability compared with its precursor
porphyrin-PEG 6. It is also interesting to note that among the
polyamine series 12−15 that diﬀer only in the number of
carbon spacers between the amine groups, conjugate 12
containing the smallest carbon backbone (2−3−2) showed

Figure 5. Subcellular ﬂuorescence of conjugate 8 in HEp2 cells at 10
μM for 6 h: (a) phase contrast, (b) overlay of theﬂuorescence of 8 and
phase contrast, (c) ER Tracker Blue/White ﬂuorescence, (e)
MitoTracker Green ﬂuorescence, (g) BODIPY Ceramide, (i)
LysoSensor Green ﬂuorescence, and (d, f, h, j) overlays of organelle
tracers with the ﬂuorescence of 8. Scale bar, 10 μm.
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surface of hCMEC/D3 cells; this result is also in agreement
with its observed lower uptake into T98G cells at early time
points. Our studies show that certain cationic polyamine and
arginine porphyrin conjugates, as well as the YRFA conjugate,
bearing stable p-carborane clusters are promising borondelivery vehicles for BNCT of brain tumors.

the highest permeability, whereas 14, with the largest backbone
(3−4−3), showed the lowest.
The above results show that the hCMEC/D3 cells form a
tight BBB-like monolayer that restricts the permeability of
boron-containing porphyrins. Previous studies have shown that
monolayers of this brain endothelial cell line indeed restrict the
uptake of many hydrophobic and hydrophilic molecules,47−51
correlating with in vivo studies. An approach to overcome the
low permeability of drugs across the BBB is the use of carrier
systems that are endocytosed by brain endothelial cells upon
receptor binding, such as immunoliposomes and other targeted
nanoparticles. Studies using hCMEC/D3 cells and drugencapsulated targeted nanoparticles have shown increasing
drug delivery across the BBB monolayer,49,55 and this might be
a more eﬃcient methodology for delivering boron to the brain.
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CONCLUSIONS
We describe the synthesis and in vitro studies of a series of
tri[(p-carboranylmethylthio)tetraﬂuorophenyl]porphyrin conjugates to glucose, arginine, linear and branched polyamines,
and tri(ethylene glycol)-YRFA. The p-carborane groups, unlike
the most common o-carboranes, are stable under the basic and
coupling conditions used to prepare the conjugates. A tetra[(pcarboranylmethylthio)tetraﬂuorophenyl]porphyrin was also
synthesized, and its crystal structure is the ﬁrst in the CSD of
a porphyrin-bearing p-carborane clusters.
None of the porphyrin conjugates were toxic to human
glioma T98G cells, both in the dark (IC50 > 400 μM) and upon
exposure to 1.5 J/cm2 light (IC50 > 100 μM), an important
feature of boron-delivery agents because of the high amount of
boron needed in BNCT (>20 μg/g tumor). Within this series
of porphyrins, the tetra(p-carboranylmethylthio)porphyrin 1
and the branched polyamine conjugate 3 accumulated the
fastest in T98G cells, but after 2 h, a plateau was reached,
whereas the arginine and glucose conjugates continued to
accumulate over time. At times >4 h, the arginine conjugate 7
had the highest uptake into cells, whereas the YRFA conjugate
8 had the least. The glucose conjugate 5 was taken up the
slowest in this series, but at times >8 h it showed similar uptake
as that of the polyamine conjugates. All compounds localized in
multiple organelles within human HEp2 cells, including the
mitochondria, lysosomes, Golgi, and ER, suggesting the
potential for multiple sites of damage upon neutron irradiation.
The hCMEC/D3 cells formed a tight BBB-like monolayer
that restricted the permeability of the porphyrin conjugates, as
indicated by their lower permeability coeﬃcients than that of
LY, as a result of their relatively high molecular weights,
hydrophobicity, and tendency for aggregation. This is the ﬁrst
investigation of the BBB permeability of boron-containing
porphyrins in an in vitro model. The hCMEC/D3 model is
easy and convenient to use, allowing high-throughput testing
and comparison of potential BNCT agents at times up to 1 h
(to ensure the integrity of the cell monolayer). The
permeability coeﬃcients for the porphyrin conjugates followed
the order 12 > 3 > 8 > 7 ∼ 15 > 9 ∼ 1 > 11 ∼ 6 > 13 > 4 ∼ 10
∼ 14 > 5. The polyamine conjugates 12 and 3 showed the
highest permeability coeﬃcients, probably as a result of
enhanced interactions with negatively charged cell membranes,
followed by the YRFA conjugate 8, which could be targeting
receptors on the cell membrane. On the other hand, the
glucose conjugate 5 showed the lowest permeability, due to its
poor aqueous solubility and its tendency for aggregation, which
prevents the targeting of GLUT receptors expressed at the
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(4) Kankaanranta, L.; Seppälä, T.; Koivunoro, H.; Saarilahti, K.;
Atula, T.; Collan, J.; Salli, E.; Kortesniemi, M.; Uusi-Simola, J.;
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